Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDINALS phase 2 trial of utreloxastat in adults with amyotrophic lateral sclerosis
NL-OMON53503Phase 2Recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing utreloxastat with placebo (2 arms). Primary endpoint: Change from baseline in ALS Functional Rating Scale-Revised after 24 weeks in ITT1. Started Oct 2023; status: recruiting.
02
Drugs
utreloxastat
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON53503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53503.